Allergen-induced increase of eosinophil cationic protein in nasal lavage fluid: effect of the glucocorticoid budesonide.
It was our aim to study the effect of nasal allergen provocation on the concentration of eosinophil cationic protein (ECP) in nasal lavage fluid, with and without glucocorticoid pretreatment. Twenty grass-pollen sensitive volunteers were provoked outside the pollen season on 2 consecutive days after pretreatment for 2 weeks with the glucocorticoid, budesonide, as a nasal spray (400 micrograms/day) and with placebo with a double-blind, crossover design. Nasal lavage fluid was repeatedly collected during a 10-hour period to study both early and late-phase responses. 99mTechnetium-albumin was added to the lavage fluid, making it possible to calculate the amount of secretion and the degree of dilution. The results were as follows: (1) There was no correlation between ECP concentration and dilution factor in the individual samples. (2) The mean concentration of ECP in lavage fluid from untreated, prechallenge noses was 400 micrograms/L. (3) The ECP level did not increase during the early phase response. (4) There was a late occurring increase in the ECP concentration (6 to 24 hours). (5) This increase was completely inhibited by budesonide pretreatment. (6) The glucocorticoid therapy also reduced the prechallenge ECP concentration. In conclusion, allergen provocation in the nose results in a late occurring increase of ECP in nasal lavage fluid, and one of the therapeutic effects of topical glucocorticoid therapy may be an inhibition of the allergen-induced increase of this cytotoxic molecule.
Department of Otorhinolaryngology, Rigshospitalet, Copenhagen, Denmark.
H
H
Bisgaard
H
H
Grønborg
N
N
Mygind
R
R
Dahl
N
N
Lindqvist
P
P
Venge
D000328:Adult; D001798:Blood Proteins / Q000032:analysis*; D019819:Budesonide; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D047091:Eosinophil Granule Proteins; D005260:Female; D006801:Humans; D008297:Male; D009297:Nasal Mucosa / Q000378:metabolism; D011282:Pregnenediones / Q000494:pharmacology / Q000627:therapeutic use; D012221:Rhinitis, Allergic, Perennial / Q000188:drug therapy; D012260:Ribonucleases; D007507:Therapeutic Irrigation
D001798:Blood Proteins; D047091:Eosinophil Granule Proteins; D011282:Pregnenediones; D019819:Budesonide; D012260:Ribonucleases